{
    "root": "be0210a1-cda6-4f01-af18-5b022bbc68a5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": "liothyronine sodium",
    "value": "20250312",
    "ingredients": [
        {
            "name": "LIOTHYRONINE SODIUM",
            "code": "GCA9VV7D2N",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6484"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GELATIN TYPE B BOVINE (160 BLOOM)",
            "code": "1T8387508X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        }
    ],
    "indications": {
        "text": "liothyronine l-triiodothyronine ( t3 ) indicated : hypothyroidism : replacement primary ( thyroidal ) , secondary ( pituitary ) , tertiary ( hypothalamic ) congenital acquired hypothyroidism ( 1.1 ) pituitary thyrotropin ( thyroid-stimulating hormone , tsh ) suppression : adjunct surgery radioiodine therapy management well-differentiated thyroid cancer ( 1.2 ) thyroid suppression test : diagnostic agent suppression tests differentiate suspected mild hyperthyroidism thyroid gland autonomy ( 1.3 ) limitations : indicated suppression benign thyroid nodules nontoxic diffuse goiter iodine-sufficient patients . ( 1 ) indicated treatment hypothyroidism recovery phase subacute thyroiditis . ( 1 )",
        "doid_entities": [
            {
                "text": "hypothyroidism (DOID:1459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1459"
            },
            {
                "text": "thyroid cancer (DOID:1781)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1781"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "hyperthyroidism (DOID:7998)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7998"
            },
            {
                "text": "goiter (DOID:12176)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12176"
            },
            {
                "text": "subacute thyroiditis (DOID:7165)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7165"
            },
            {
                "text": "thyroiditis (DOID:7166)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7166"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer liothyronine sodium tablets orally daily individual according patient response laboratory findings ( 2.1 ) full prescribing information recommended hypothyroidism ( 2.2 ) tsh suppression well-differentiated thyroid cancer ( 2.3 ) thyroid suppression test ( 2.4 ) switching patient liothyronine sodium tablets discontinue levothyroxine therapy initiate liothyronine sodium tablets low . gradually increase dose according patient \u2019 response ( 2.5 ) adequacy therapy determined periodic monitoring tsh t3 levels well status ( 2.6 )",
        "doid_entities": [
            {
                "text": "hypothyroidism (DOID:1459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1459"
            },
            {
                "text": "thyroid cancer (DOID:1781)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1781"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "product : 50090-7518 ndc : 50090-7518-0 100 tablet bottle ndc : 50090-7518-1 90 tablet bottle",
    "adverseReactions": "liothyronine sodium tablets contraindicated patients uncorrected adrenal insufficiency [ ( 5.3 ) ] .",
    "indications_original": "Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism (1.1) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer (1.2) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy (1.3) Limitations of Use: Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. (1) Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. (1)",
    "contraindications_original": "Administer liothyronine sodium tablets orally once daily and individual dosage according to patient response and laboratory findings (2.1) See full prescribing information for recommended dosage for hypothyroidism (2.2) TSH suppression in well-differentiated thyroid cancer (2.3) and for thyroid suppression test (2.4) When switching a patient to liothyronine sodium tablets discontinue levothyroxine therapy and initiate liothyronine sodium tablets at a low dosage. Gradually increase the dose according to the patient\u2019s response (2.5) Adequacy of therapy determined with periodic monitoring of TSH and T3 levels as well as clinical status (2.6)",
    "warningsAndPrecautions_original": "Product:    50090-7518\n                  NDC:    50090-7518-0   100 TABLET in a BOTTLE\n                  NDC:    50090-7518-1   90 TABLET in a BOTTLE",
    "adverseReactions_original": "Liothyronine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.3)].",
    "drug": [
        {
            "name": "liothyronine sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6484"
        }
    ]
}